These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

561 related items for PubMed ID: 33841390

  • 1. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
    Didona D, Scarsella L, Fehresti M, Solimani F, Juratli HA, Göbel M, Mühlenbein S, Holiangu L, Pieper J, Korff V, Schmidt T, Sitaru C, Eming R, Hertl M, Pollmann R.
    Front Immunol; 2021; 12():569287. PubMed ID: 33841390
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
    Daneshpazhooh M, Ghiasi M, Lajevardi V, Nasiri N, Balighi K, Teimourpour A, Khosravi H, Saeidi V, Mahmoudi H, Chams-Davatchi C.
    Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
    [Abstract] [Full Text] [Related]

  • 4. BP180- and BP230-specific IgG autoantibodies in pruritic disorders of the elderly: a preclinical stage of bullous pemphigoid?
    Schmidt T, Sitaru C, Amber K, Hertl M.
    Br J Dermatol; 2014 Aug; 171(2):212-9. PubMed ID: 24601973
    [Abstract] [Full Text] [Related]

  • 5. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
    Fania L, Caldarola G, Müller R, Brandt O, Pellicano R, Feliciani C, Hertl M.
    Clin Immunol; 2012 Jun; 143(3):236-45. PubMed ID: 22534318
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.
    Schneiderbauer R, Martinache S, Engstner M, Enk AH, Hadaschik EN.
    Dermatol Ther; 2016 Nov; 29(6):419-423. PubMed ID: 27550573
    [Abstract] [Full Text] [Related]

  • 9. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y, Nishie W, Izumi K, Shimizu H.
    Front Immunol; 2019 Nov; 10():1224. PubMed ID: 31191560
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
    Ishiura N, Fujimoto M, Watanabe R, Nakashima H, Kuwano Y, Yazawa N, Echigo T, Okochi H, Tamaki K.
    J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
    [Abstract] [Full Text] [Related]

  • 12. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
    Hayakawa T, Teye K, Hachiya T, Uehara R, Hashiguchi M, Kawakami T, Li X, Tsuchisaka A, Ohara K, Sogame R, Koga H, Hamada T, Ohata C, Furumura M, Ishii N, Fukano H, Shimozato K, Hashimoto T.
    Eur J Dermatol; 2016 Apr 01; 26(2):155-63. PubMed ID: 27087683
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230.
    Skaria M, Jaunin F, Hunziker T, Riou S, Schumann H, Bruckner-Tuderman L, Hertl M, Bernard P, Saurat JH, Favre B, Borradori L.
    J Invest Dermatol; 2000 May 01; 114(5):998-1004. PubMed ID: 10771483
    [Abstract] [Full Text] [Related]

  • 15. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
    Hashimoto T, Ohzono A, Teye K, Numata S, Hiroyasu S, Tsuruta D, Hachiya T, Kuroda K, Hashiguchi M, Kawakami T, Ishii N.
    Br J Dermatol; 2017 Jul 01; 177(1):141-151. PubMed ID: 27716903
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms.
    Julio TA, Vernal S, Massaro JD, Silva MC, Donadi EA, Moriguti JC, Roselino AM.
    Immunol Res; 2018 Oct 01; 66(5):567-576. PubMed ID: 30220011
    [Abstract] [Full Text] [Related]

  • 19. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
    Fichel F, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Michel C, Jegou J, Grange F, Antonicelli F, Bernard P.
    JAMA Dermatol; 2014 Jan 01; 150(1):25-33. PubMed ID: 24226428
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.